CN116268390A - 一种提高记忆力、学习力和认知力的组合物及其制备方法 - Google Patents
一种提高记忆力、学习力和认知力的组合物及其制备方法 Download PDFInfo
- Publication number
- CN116268390A CN116268390A CN202310306191.3A CN202310306191A CN116268390A CN 116268390 A CN116268390 A CN 116268390A CN 202310306191 A CN202310306191 A CN 202310306191A CN 116268390 A CN116268390 A CN 116268390A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- composition
- learning
- memory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 230000015654 memory Effects 0.000 title claims abstract description 55
- 230000013016 learning Effects 0.000 title claims abstract description 38
- 230000019771 cognition Effects 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 104
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 44
- 239000002994 raw material Substances 0.000 claims abstract description 42
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 29
- 244000299461 Theobroma cacao Species 0.000 claims abstract description 27
- 235000009470 Theobroma cacao Nutrition 0.000 claims abstract description 27
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 26
- GWHCXVQVJPWHRF-KTKRTIGZSA-N (15Z)-tetracosenoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-KTKRTIGZSA-N 0.000 claims abstract description 22
- XJXROGWVRIJYMO-SJDLZYGOSA-N Nervonic acid Natural products O=C(O)[C@@H](/C=C/CCCCCCCC)CCCCCCCCCCCC XJXROGWVRIJYMO-SJDLZYGOSA-N 0.000 claims abstract description 22
- GWHCXVQVJPWHRF-UHFFFAOYSA-N cis-tetracosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229960003080 taurine Drugs 0.000 claims abstract description 22
- 241000899834 Obovaria olivaria Species 0.000 claims abstract description 20
- 241000192710 Microcystis aeruginosa Species 0.000 claims abstract description 16
- 241000195493 Cryptophyta Species 0.000 claims abstract description 12
- 240000000950 Hippophae rhamnoides Species 0.000 claims abstract 5
- 239000000284 extract Substances 0.000 claims description 34
- 239000011812 mixed powder Substances 0.000 claims description 21
- 238000002156 mixing Methods 0.000 claims description 21
- 238000007873 sieving Methods 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 14
- 239000003937 drug carrier Substances 0.000 claims description 13
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 11
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 11
- 239000009429 Ginkgo biloba extract Substances 0.000 claims description 11
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 11
- 235000002789 Panax ginseng Nutrition 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 11
- 229920002770 condensed tannin Polymers 0.000 claims description 11
- 239000000787 lecithin Substances 0.000 claims description 11
- 229940067606 lecithin Drugs 0.000 claims description 11
- 235000010445 lecithin Nutrition 0.000 claims description 11
- 235000018192 pine bark supplement Nutrition 0.000 claims description 11
- 229940106796 pycnogenol Drugs 0.000 claims description 11
- 238000005303 weighing Methods 0.000 claims description 11
- 244000221226 Armillaria mellea Species 0.000 claims description 10
- 235000011569 Armillaria mellea Nutrition 0.000 claims description 10
- DAYLJWODMCOQEW-TURQNECASA-O NMN(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(O)=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-O 0.000 claims description 10
- 230000002708 enhancing effect Effects 0.000 claims description 10
- 239000012467 final product Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- 230000000694 effects Effects 0.000 abstract description 46
- 210000004556 brain Anatomy 0.000 abstract description 27
- 230000003930 cognitive ability Effects 0.000 abstract description 10
- 230000008451 emotion Effects 0.000 abstract description 10
- 230000007423 decrease Effects 0.000 abstract description 9
- 210000000653 nervous system Anatomy 0.000 abstract description 6
- 230000008897 memory decline Effects 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 208000010877 cognitive disease Diseases 0.000 abstract description 4
- 201000001119 neuropathy Diseases 0.000 abstract description 4
- 230000007823 neuropathy Effects 0.000 abstract description 4
- 208000033808 peripheral neuropathy Diseases 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 230000006999 cognitive decline Effects 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 3
- 208000019022 Mood disease Diseases 0.000 abstract description 2
- 241000229143 Hippophae Species 0.000 description 25
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 22
- 230000003935 attention Effects 0.000 description 12
- 208000024827 Alzheimer disease Diseases 0.000 description 11
- 238000011161 development Methods 0.000 description 10
- 210000002569 neuron Anatomy 0.000 description 10
- 230000032683 aging Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 8
- 210000004958 brain cell Anatomy 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 229940076279 serotonin Drugs 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 244000299492 Thespesia populnea Species 0.000 description 4
- 235000009430 Thespesia populnea Nutrition 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000005013 brain tissue Anatomy 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 208000027534 Emotional disease Diseases 0.000 description 3
- 206010039966 Senile dementia Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000004126 nerve fiber Anatomy 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 241001083841 Aquatica Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 230000006974 Aβ toxicity Effects 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003941 amyloidogenesis Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 210000002932 cholinergic neuron Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WGTASENVNYJZBK-UHFFFAOYSA-N 3,4,5-trimethoxyamphetamine Chemical compound COC1=CC(CC(C)N)=CC(OC)=C1OC WGTASENVNYJZBK-UHFFFAOYSA-N 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000223600 Alternaria Species 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000723418 Carya Species 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- OEIJRRGCTVHYTH-UHFFFAOYSA-N Favan-3-ol Chemical compound OC1CC2=CC=CC=C2OC1C1=CC=CC=C1 OEIJRRGCTVHYTH-UHFFFAOYSA-N 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000003935 Hippophae Nutrition 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- DFQMOFZOIAKCGI-UHFFFAOYSA-N OC=1C(=C(C(=C2NC(=C(CCN)C12)O)O)O)O Chemical compound OC=1C(=C(C(=C2NC(=C(CCN)C12)O)O)O)O DFQMOFZOIAKCGI-UHFFFAOYSA-N 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 108010053210 Phycocyanin Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 241000579741 Sphaerotheca <fungi> Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010065604 Suicidal behaviour Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 108091007736 alpha-secretases Proteins 0.000 description 1
- 102000038380 alpha-secretases Human genes 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000006502 antiplatelets effects Effects 0.000 description 1
- 230000035045 associative learning Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108091007737 beta-secretases Proteins 0.000 description 1
- 208000014679 binge eating disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 230000005189 cardiac health Effects 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000004060 excitotoxin Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 108091007739 gamma-secretases Proteins 0.000 description 1
- 102000038383 gamma-secretases Human genes 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 231100000783 metal toxicity Toxicity 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001067 neuroprotector Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940117803 phenethylamine Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000004793 poor memory Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/09—Mashed or comminuted products, e.g. pulp, purée, sauce, or products made therefrom, e.g. snacks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
- A23L25/30—Mashed or comminuted products, e.g. pulp, pastes, meal, powders; Products made therefrom, e.g. blocks, flakes, snacks; Liquid or semi-liquid products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/10—Natural spices, flavouring agents or condiments; Extracts thereof
- A23L27/12—Natural spices, flavouring agents or condiments; Extracts thereof from fruit, e.g. essential oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/10—Natural spices, flavouring agents or condiments; Extracts thereof
- A23L27/14—Dried spices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/748—Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本申请提出了一种提高记忆力、学习力和认知力的组合物及其制备方法,涉及保健品技术领域。一种提高记忆力、学习力和认知力的组合物及其制备方法,包括如下原料:神经酸0.1‑0.5份、牛磺酸0.5‑2份、沙棘果粉1‑5份、可可粉1‑5份、山核桃粉1‑5份和水华束丝藻粉2‑8份。本申请通过将不同原料进行复配,由于不同原料的协同作用,可改善大脑和神经系统的能力,综合表现出来为增强认知能力,提高注意力和记忆力,能够有效改善记忆力衰退、认知能力下降和学习能力减退的情况,且本申请的组合物没有毒副作用和依赖性,起效快,作用效果明显,疗效稳定。本申请的组合物能够调节人体情绪,治疗情绪障碍,对神经病有很好的治疗效果。
Description
技术领域
本申请涉及保健品技术领域,具体而言,涉及一种提高记忆力、学习力和认知力的组合物及其制备方法。
背景技术
认知能力是指人脑加工、储存和提取信息的能力,即人们对事物的构成、性能与他物的关系、发展的动力、发展方向以及基本规律的把握能力。它是人们成功的完成活动最重要的心理条件。知觉、记忆、注意、思维和想象的能力都被认为是认知能力。
阿尔茨海默氏病(AD)会导致记忆力和其他方面的认知能力下降,这是60%以上的痴呆症病例的原因。AD发生的机制目前尚未完全研究透彻,只是存在多种假说,包括胆碱能神经元假说、Aβ毒性假说和氧化应激不平衡假说等。其中Aβ毒性假说是AD致病机制中占主导地位的学说。Aβ主要是由α、β和γ分泌酶分泌不正常,引起APP水解异常所致。Aβ具有神经毒性,当其含量升高后,细胞并不能将其代谢掉,反而会在细胞中大量积累,形成Aβ老年斑,促使神经元细胞损伤或死亡,造成记忆和认知损伤。胆碱能神经元假说是指胆碱能神经递质是脑组织中的重要化学物质,发生AD时脑内的胆碱能神经元减少,导致乙酰胆碱(ACh)合成、储存和释放减少,进而引起记忆和识别功能障碍。另外神经元细胞对氧化应激尤为敏感。研究发现,AD患者的神经元长时间处于氧化应激状态,ROS可损伤神经元内多种生物大分子和生物膜。由此,氧化不平衡假说与AD发病机制紧密相关的假说被提出。
基于以上假说,目前已有超过1000种化合物或药物制剂被研究并尝试用于AD的预防。现有的上市药物多是针对单一靶点作为脑代谢改善剂或神经保护剂。然而其效果并不令人满意,大多都存在药物起效慢,不便于制备使用,效果不十分明显和疗效不稳定等问题。
发明内容
本申请的目的在于提供一种提高记忆力、学习力和认知力的组合物,此组合物具有起效快、效果明显和疗效稳定的优点。
本申请的另一目的在于提供一种提高记忆力、学习力和认知力的组合物的制备方法,以制备此组合物。
为解决上述问题,本发明采用的技术方法为:
一方面,本申请实施例提供一种提高记忆力、学习力和认知力的组合物,包括如下原料:神经酸0.1-0.5份、牛磺酸0.5-2份、沙棘果粉1-5份、可可粉1-5份、山核桃粉1-5份和水华束丝藻粉2-8份。
另一方面,本申请实施例提供一种提高记忆力、学习力和认知力的组合物的制备方法,包括如下步骤:
称取对应的原料,并将各原料混合并过筛后,得到混合粉;
将药学上可接受的载体或辅料过筛,与混合粉混合均匀,再制成颗粒,得到组合物成品。
相对于现有技术,本申请的发明至少具有如下优点或有益效果:
本申请通过将不同原料进行复配,由于不同原料的协同作用,可以改善大脑和神经系统的能力,综合表现出来为增强认知能力,提高注意力和记忆力,能够有效改善记忆力衰退、认知能力下降和学习能力减退的情况,且本申请的组合物没有毒副作用和依赖性,起效快,作用效果明显,且疗效稳定。本申请所添加的沙棘果粉、水华束丝藻粉和可可粉均能够调节人体情绪,因此组合物还能够调节人体情绪,治疗情绪障碍。此外,本申请的组合还对神经病有很好的治疗效果。
具体实施方式
为使本申请实施例的目的、技术方案和优点更加清楚,下面将对本申请实施例中的技术方案进行清楚、完整地描述。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
需要说明的是,在不冲突的情况下,本申请中的实施例及实施例中的特征可以相互组合。下面将参考具体实施例来详细说明本申请。
神经酸:神经酸是神经细胞特别是大脑细胞、视神经细胞、周围神经生长再发育和维持生理功能必需的“高级营养素”,营养大脑的珍品;由于人体自身很难生成,体外摄取非常重要。它可以修复疏通神经纤维,提高脑神经的活跃、恢复神经末梢活性,促进神经细胞生长和发育,防止神经纤维萎缩;抑制大脑神经纤维和神经细胞的歧变和衰退,促使脑损伤恢复,防止大脑组织的塌陷、萎缩及硬化;促进脑组织发育同时,又降低了脑细胞内脂褐素的积累,从而防止脑细胞衰老而起到使人长寿的目的;改善大脑血液循环,保障脑细胞血氧充分供给,促进新陈代谢;醒神健脑,营养脑神经,调节脑细胞功能,增强信息在脑细胞之间的连接,增强脑细胞能量,促进细胞增值分化,恢复大脑清晰认知、辨别能力及学习和思维记忆功能;促进大脑组织生长发育和功能完善,提高大脑的智能反应速度,增强自我运动和感觉功能,实现脑瘫患儿生活自立能力和学习能力。
牛磺酸:牛磺酸是一种含硫的非蛋白质氨基酸,存在于动物体内,提取后作用于人体可具有一定的治疗功效。具有消炎抗菌、抗病毒、镇静和镇痛的作用,可作用于人体多个系统。牛磺酸能促进大脑神经系统的生长发育和细胞分化,具有抑制细胞活性、调节细胞传导的作用。且牛磺酸可以增强营养物质对细胞的通透性,有助于机体对营养元素的吸收,对儿童脑神经的生长发育可起到促进作用。
沙棘果粉:沙棘果粉主要功效是抗氧化,同时具有一定减缓衰老的效果。沙棘果粉是用沙棘鲜汁经过喷雾干燥制成的一种食物,里面有大量的维生素C及抗氧化物质,沙棘果粉中还含有沙棘油成分,有缓解疲劳和增强机体免疫力的作用,还具有防病延缓衰老的作用。沙棘含有独特的天然植物“情绪调节素”五-羟色胺(5-HT),能够调节紧张情绪,激活性腺功能,通过增强神经系统功能与精神活动状况的稳定性,缓解神经衰弱、失眠和烦躁便秘等症状,有效预防老年痴呆和脑萎缩症状,其还能够调节睡眠,体温,肌肉收缩,记忆,学习,情绪,食欲和血液凝固。在低的血清素(五-羟色胺)水平,增加血清素的量可以减少几个障碍的症状。沙棘果粉一旦被吸收到循环中,部分5-HTP行进至脑,在那里它被转换成血清素(5-羟色胺或5-HT),这有助于调节情绪,行为,食欲,睡眠。血清素的低水平与抑郁,失眠,焦虑,经前期综合征,狂饮-进食障碍,纤维肌痛和偏头痛有关。5-羟色胺水平低与各种各样的情绪和行为障碍,包括抑郁,焦虑,自杀行为与强迫症有关。5-羟色胺还能增强记忆力,并能保护神经元免受“兴奋神经毒素”的损害。因此充足的5-羟色胺确实能在老化过程中防止脑损害发生。沙棘果粉具有抗氧化作用。此外,沙棘果粉还具有补充营养成分、调节免疫功能、保护心脑血管和促进发育等功效。
可可粉:可可粉中含有丰富的蛋白质、硬脂酸、维生素B2、软脂酸、维生素A、维生素E、维生素D、钾、镁、钙、铁等多种营养元素。其中还含有一定的生物碱成分,能够起到缓解疲劳的作用。可可粉有助于提高注意力和记忆力,也有利于恢复睡眠。适量食用可可粉可以促进大脑的正常衰老,并抵御痴呆、中风、认知能力下降、记忆力差和情绪障碍,由于含有苯乙胺,这是一种天然的抗抑郁物质,具有提升情绪,减少压力的作用。可可粉中还含有丰富的类黄酮物质,主要是黄烷醇和原花青素成分,可以延长体内其它抗氧化剂的作用时间,同时还可以促进血管舒张,从而起到保护血管的作用。
山核桃粉:含有丰富的维生素E,可以有效抗氧化,抗衰老,保护肌肤,还可以防止血液中的自由基对内脏组织的破坏,延缓衰老过程。山核桃粉含有丰富的维生素B1和维生素B2,有助于改善神经系统的功能,特别是对于抑郁、焦虑等精神疾病有一定的调节作用。
水华束丝藻粉:水华束丝藻可促进干细胞进入循环中,进而帮助身体各部位的修复,其含有高生物利用度的Omega-3脂肪酸、类胡萝卜素和叶绿素,可促进心脏健康并有益于注意力缺失的治疗。水华束丝藻含有大量神经传递素苯乙胺,能增加人体脑部的多巴胺水平,进而促进内啡肽循环。含有藻蓝蛋白,有助于预防发炎和疼痛,保护人体免受重金属毒性和农药的侵害。
银杏叶提取物:具有一定抗血小板的作用,可以抑制血小板聚集,可以起到预防血栓的作用;具有自由基的清除作用,可以清除体内过多的自由基,抑制细胞膜的脂质发生过氧化反应,从而保护细胞膜,防止自由基对机体造成血栓;对循环系统有一定的调整作用,可以刺激儿茶酚胺的释放和抑制降解,通过刺激前列腺环素和内皮舒张因子生成,而产生动脉舒张的作用;还有一定血液动力学的改善作用,可以降低全血粘度,增进红血球和白血球的可塑性,改善血循环;另外也具有组织保护的作用,它可以增加缺血组织对氧气以及葡萄糖的供应量,可以改善患者的相关功能。
熊苔提取物:可以提供注意力集中,预防老年痴呆,减少焦虑,为大脑提供能量。
磷脂酰丝氨酸:能够帮助细胞壁保持柔韧性,并且能够增强传送大脑信号的神经递质的效率,帮助大脑高效率运转,激发大脑的活化状态;可以短期增强记忆力,且比较安全,补充磷脂酰丝胺酸能增加脑突刺数目、脑细胞膜的流动性及促进脑细胞中葡萄糖代谢,从而使脑细胞更活跃,促进注意力集中、提高警觉性和记忆力;还有助于缓解大脑疲劳,修复脑部细胞损伤。
蜜环菌菌粉:具有延缓衰老和催眠镇静功效,可以减缓记忆力衰退情况。
烟酰胺单核苷酸:可以减少人体淀粉样蛋白沉积,缩小老年斑斑块,抑制氧化应激反应,同时恢复神经元细胞的活力,提升细胞内的辅酶NAD+的水平,改善线粒体的功能,增加能量的供应,增加对神经的供血、供氧,维持脑部的年轻态。
红参提取物:红参提取物及其所含的皂苷具有捉高记忆能力、学习能力并改善记忆衰退的功效。红参提取物还有着抗疲劳的作用,不仅对中枢神经系统有兴奋作用,而且红参提取物增强机体对一切非特异性刺激的适应能力,能减少疲劳感。
卵磷脂:卵磷脂中所含的乙酰进入人体内与胆碱结合,构成乙酰胆碱。乙酰胆碱不仅是一种记忆素,还是一种神经传导物质,其含量越高,人的神经反应速度就越快,人的记忆力也就随之加强。卵磷脂有助于促进儿童大脑的生长发育,可以开发智力,提高注意力,缓解精神紧张、记忆减退和疲倦等不良病症。
碧萝芷提取物:碧萝芷提取物具有很强的抗氧化作用,而且安全性也比较高,是迄今为止发现的最有效的天然抗氧化剂。
本申请实施例提供一种提高记忆力、学习力和认知力的组合物,包括如下原料:神经酸0.1-0.5份、牛磺酸0.5-2份、沙棘果粉1-5份、可可粉1-5份、山核桃粉1-5份和水华束丝藻粉2-8份。
本申请通过将不同原料进行复配,由于不同原料的协同作用,可以改善大脑和神经系统的能力,综合表现出来为增强认知能力,提高注意力和记忆力,能够有效改善记忆力衰退、认知能力下降和学习能力减退的情况,且本申请的组合物没有毒副作用和依赖性,起效快,作用效果明显,且疗效稳定。本申请所添加的沙棘果粉、水华束丝藻粉和可可粉均能够调节人体情绪,因此组合物还能够调节人体情绪,治疗情绪障碍。此外,本申请的组合还对神经病有很好的治疗效果。
具体来说,本申请通过以神经酸补充大脑所需,以牛磺酸促进大脑的生长发育和系统分化,有助于人体对神经酸的吸收,且沙棘果粉、可可粉、山核桃粉可以调节本组合物的口味,使得其更易于被接受,同时还能够起到抗氧化、保养血管和延缓神经细胞衰老的作用,水华束丝藻粉的参与可以补充Omega-3,从而延缓记忆力衰退。多种原料共同作用,从而快速对人体起到提高认知能力、注意力和记忆力的作用。
在本申请的一些实施例中,上述提高记忆力、学习力和认知力的组合物包括如下原料:神经酸0.1-0.3份、牛磺酸0.8-1.5份、沙棘果粉2-4份、可可粉2-4份、山核桃粉2-4份和水华束丝藻粉4-6份。
在本申请的一些实施例中,上述提高记忆力、学习力和认知力的组合物包括如下原料:神经酸0.3份、牛磺酸1份、沙棘果粉3份、可可粉3份、山核桃粉3份和水华束丝藻粉5份。
在本申请的一些实施例中,上述提高记忆力、学习力和认知力的组合物还包括如下原料:银杏叶提取物1-3份、熊苔提取物0.01-0.03份、磷脂酰丝氨酸0.01-0.03份、蜜环菌菌粉1-3份、烟酰胺单核苷酸1.5-5份、红参提取物0.01-0.03份、卵磷脂0.01-0.03份和碧萝芷提取物0.01-0.05份。
银杏叶提取物可以清除自由基,抗衰老,促进血液循环,提高供氧量,从而避免细胞因缺氧而导致的学习能力下降,卵磷脂可以提高记忆力,缓解紧张情绪,熊苔提取物可以集中注意力,磷脂酰丝氨酸能够促进记忆力提高,碧萝芷提取物、蜜环菌菌粉可以协同银杏叶提取物起到抗衰老的作用,烟酰胺单核苷酸可以清除人体淀粉样蛋白沉积,避免老年痴呆,红参提取物能够提高学习能力和记忆力。在增加上述多种原料后,能够增强本组合物提高认知能力、注意力和记忆力的作用。
在本申请的一些实施例中,上述提高记忆力、学习力和认知力的组合物包括如下原料:神经酸0.3份、牛磺酸1份、沙棘果粉3份、可可粉3份、山核桃粉3份、水华束丝藻粉5份、银杏叶提取物2份、熊苔提取物0.02份、磷脂酰丝氨酸0.02份、蜜环菌菌粉2份、烟酰胺单核苷酸3份、红参提取物0.02份、卵磷脂0.02份和碧萝芷提取物0.03份。
本申请实施例还提供一种提高记忆力、学习力和认知力的组合物的制备方法,包括如下步骤:
称取对应的原料,并将各原料混合并过筛后,得到混合粉;
将药学上可接受的载体或辅料过筛,与混合粉混合均匀,再制成颗粒,得到组合物成品。
在本申请的一些实施例中,上述混合粉过筛尺寸为50-150目筛,所述药学上可接受的载体或辅料过筛尺寸为50-150目。
在本申请的一些实施例中,上述药学上可接受的载体或辅料包括但不限于淀粉、蔗糖、乳糖、微晶纤维素、硫酸钙、甘露醇、山梨醇和碳酸钙。
以下结合实施例对本申请的特征和性能作进一步的详细描述。
实施例1
一种提高记忆力、学习力和认知力的组合物的制备方法,包括如下步骤:
原料:神经酸0.1g、牛磺酸0.5g、沙棘果粉1g、可可粉1g、山核桃粉1g和水华束丝藻粉2g。
称取对应的原料,并将各原料混合并过50目筛后,得到混合粉;
将药学上可接受的载体或辅料(淀粉10g)过50目筛,与混合粉混合均匀,再制成颗粒,得到组合物成品。
实施例2
一种提高记忆力、学习力和认知力的组合物的制备方法,包括如下步骤:
原料:神经酸0.1g、牛磺酸0.8g、沙棘果粉2g、可可粉2g、山核桃粉2g和水华束丝藻粉4g。
称取对应的原料,并将各原料混合并过50目筛后,得到混合粉;
将药学上可接受的载体或辅料(淀粉10g)过50目筛,与混合粉混合均匀,再制成颗粒,得到组合物成品。
实施例3
一种提高记忆力、学习力和认知力的组合物的制备方法,包括如下步骤:
原料:神经酸0.3g、牛磺酸1g、沙棘果粉3g、可可粉3g、山核桃粉3g和水华束丝藻粉5g。
称取对应的原料,并将各原料混合并过100目筛后,得到混合粉;
将药学上可接受的载体或辅料(淀粉10g)过100目筛,与混合粉混合均匀,再制成颗粒,得到组合物成品。
实施例4
一种提高记忆力、学习力和认知力的组合物的制备方法,包括如下步骤:
原料:神经酸0.5g、牛磺酸2g、沙棘果粉5g、可可粉5g、山核桃粉5g和水华束丝藻粉8g。
称取对应的原料,并将各原料混合并过150目筛后,得到混合粉;
将药学上可接受的载体或辅料(淀粉10g)过150目筛,与混合粉混合均匀,再制成颗粒,得到组合物成品。
实施例5
一种提高记忆力、学习力和认知力的组合物的制备方法,包括如下步骤:
原料:神经酸0.1g、牛磺酸0.5g、沙棘果粉1g、可可粉1g、山核桃粉1g、水华束丝藻粉2g、银杏叶提取物1g、熊苔提取物0.01g、磷脂酰丝氨酸0.01g、蜜环菌菌粉1g、烟酰胺单核苷酸1.5g、红参提取物0.01g、卵磷脂0.01g和碧萝芷提取物0.01g。
称取对应的原料,并将各原料混合并过50目筛后,得到混合粉;
将药学上可接受的载体或辅料(淀粉10g)过50目筛,与混合粉混合均匀,再制成颗粒,得到组合物成品。
实施例6
一种提高记忆力、学习力和认知力的组合物的制备方法,包括如下步骤:
原料:神经酸0.3g、牛磺酸1g、沙棘果粉3g、可可粉3g、山核桃粉3g、水华束丝藻粉5g、银杏叶提取物2g、熊苔提取物0.02g、磷脂酰丝氨酸0.02g、蜜环菌菌粉2g、烟酰胺单核苷酸3g、红参提取物0.02g、卵磷脂0.02g和碧萝芷提取物0.03g。
称取对应的原料,并将各原料混合并过100目筛后,得到混合粉;
将药学上可接受的载体或辅料(淀粉10g)过100目筛,与混合粉混合均匀,再制成颗粒,得到组合物成品。
实施例7
一种提高记忆力、学习力和认知力的组合物的制备方法,包括如下步骤:
原料:神经酸0.5g、牛磺酸2g、沙棘果粉5g、可可粉5g、山核桃粉5g、水华束丝藻粉8g、银杏叶提取物3g、熊苔提取物0.03g、磷脂酰丝氨酸0.03g、蜜环菌菌粉3g、烟酰胺单核苷酸5g、红参提取物0.03g、卵磷脂0.03g和碧萝芷提取物0.05g。
称取对应的原料,并将各原料混合并过150目筛后,得到混合粉;
将药学上可接受的载体或辅料(淀粉10g)过150目筛,与混合粉混合均匀,再制成颗粒,得到组合物成品。
实验例
(一)、毒性测试
样品制备:
原料:神经酸0.5g、牛磺酸2g、沙棘果粉5g、可可粉5g、山核桃粉5g、水华束丝藻粉8g、银杏叶提取物3g、熊苔提取物0.03g、磷脂酰丝氨酸0.03g、蜜环菌菌粉3g、烟酰胺单核苷酸5g、红参提取物0.03g和碧萝芷提取物0.05g。
称取对应的原料,并将各原料混合并过150目筛后,得到样品。
选择SPF级SD种健康大鼠60只,随机分为3组,每组20只。对大鼠进行30天喂养试验,以2.50g/kg·bw、5.00g/kg·bw、10.00g/kg·bw剂量的上述样品,去辅料样品给大鼠灌胃30天,实验期间,动物生长发育良好,各剂量组体重、增重、食物利率、血常规指标、血生化指标、脏器重量及脏器/体重比值与对照组比较,无显著性差异(P>0.05)。大体解剖和组织病理检查未见明显与样品有关的异常改变,这说明本申请制备的组合物在30天喂养后对大鼠未见明显毒副作用。
(二)、记忆力改善实验
样品:实施例3、实施例5和实施例6制备的组合物。人拟用剂量为4g/60kg。
受试对象:受试者从未接受过类似测试,短期内未服用可以提高记忆力、学习力和认知力的物品。并在服用受试样品前对受试者进行第一次记忆商测试后,按记忆商将受试者双盲法随机分为受试组与对照组,尽可能考虑文化水平、年龄等。受试者共200人,分为4组,每组50人。
实验方法:1-3组服用本申请制备的组合物,4组服用安慰剂。每人每日按照每日早晚各一次,每次2g服用,持续一个月。
1个月后检测受试对象的数值顺序、图片回忆、视觉再认、视觉再生、联想学习、触摸测验、理解记忆和背数字的情况,实验结果如表1所示。
表1
项目 | 1组 | 2组 | 3组 | 4组 |
数值顺序 | 21.65±1.13 | 21.73±0.59 | 22.25±0.93 | 21.19±0.83 |
图片回忆 | 6.35±0.51 | 6.49±0.46 | 6.55±0.89 | 6.08±0.75 |
视觉再认 | 6.54±0.61 | 6.78±0.62 | 6.93±0.53 | 6.25±0.63 |
视觉再生 | 5.12±0.57 | 5.28±0.69 | 5.38±0.97 | 5.04±0.47 |
联想学习 | 10.58±0.68 | 10.95±0.72 | 11.18±0.61 | 10.17±0.64 |
触摸测验 | 8.28±0.92 | 8.39±0.78 | 8.45±0.41 | 8.19±0.51 |
理解记忆 | 8.73±0.67 | 8.91±0.42 | 9.09±0.85 | 8.51±0.57 |
背数字 | 8.33±0.45 | 8.67±0.44 | 8.97±0.72 | 8.21±0.38 |
根据多项实验结果,可以看出,服用本申请制备的组合物对于受试者的记忆力有较好的改善效果。且对比实施例1-4组,可以看出3组的效果最佳,这说明实施例6制备的组合物效果最佳。
综上所述,本申请通过将不同原料进行复配,由于不同原料的协同作用,可以改善大脑和神经系统的能力,综合表现出来为增强认知能力,提高注意力和记忆力,能够有效改善记忆力衰退、认知能力下降和学习能力减退的情况,且本申请的组合物没有毒副作用和依赖性,起效快,作用效果明显,且疗效稳定。本申请所添加的沙棘果粉、水华束丝藻粉和可可粉均能够调节人体情绪,因此组合物还能够调节人体情绪,治疗情绪障碍。此外,本申请的组合还对神经病有很好的治疗效果。
以上所描述的实施例是本申请一部分实施例,而不是全部的实施例。本申请的实施例的详细描述并非旨在限制要求保护的本申请的范围,而是仅仅表示本申请的选定实施例。基于本申请中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本申请保护的范围。
Claims (7)
1.一种提高记忆力、学习力和认知力的组合物,其特征在于,包括如下原料:神经酸0.1-0.5份、牛磺酸0.5-2份、沙棘果粉1-5份、可可粉1-5份、山核桃粉1-5份和水华束丝藻粉2-8份。
2.根据权利要求1所述的一种提高记忆力、学习力和认知力的组合物,其特征在于,所述提高记忆力、学习力和认知力的组合物包括如下原料:神经酸0.1-0.3份、牛磺酸0.8-1.5份、沙棘果粉2-4份、可可粉2-4份、山核桃粉2-4份和水华束丝藻粉4-6份。
3.根据权利要求1所述的一种提高记忆力、学习力和认知力的组合物,其特征在于,所述提高记忆力、学习力和认知力的组合物包括如下原料:神经酸0.3份、牛磺酸1份、沙棘果粉3份、可可粉3份、山核桃粉3份和水华束丝藻粉5份。
4.根据权利要求1所述的一种提高记忆力、学习力和认知力的组合物,其特征在于,所述提高记忆力、学习力和认知力的组合物还包括如下原料:银杏叶提取物1-3份、熊苔提取物0.01-0.03份、磷脂酰丝氨酸0.01-0.03份、蜜环菌菌粉1-3份、烟酰胺单核苷酸1.5-5份、红参提取物0.01-0.03份、卵磷脂0.01-0.03份和碧萝芷提取物0.01-0.05份。
5.根据权利要求1所述的一种提高记忆力、学习力和认知力的组合物,其特征在于,所述提高记忆力、学习力和认知力的组合物包括如下原料:神经酸0.3份、牛磺酸1份、沙棘果粉3份、可可粉3份、山核桃粉3份、水华束丝藻粉5份、银杏叶提取物2份、熊苔提取物0.02份、磷脂酰丝氨酸0.02份、蜜环菌菌粉2份、烟酰胺单核苷酸3份、红参提取物0.02份、卵磷脂0.02份和碧萝芷提取物0.03份。
6.如权利要求1-5任意一项所述的一种提高记忆力、学习力和认知力的组合物的制备方法,其特征在于,包括如下步骤:
称取对应的原料,并将各原料混合并过筛后,得到混合粉;
将药学上可接受的载体或辅料过筛,与混合粉混合均匀,再制成颗粒,得到组合物成品。
7.根据权利要求6所述的一种提高记忆力、学习力和认知力的组合物的制备方法,其特征在于,所述混合粉过筛尺寸为50-150目筛,所述药学上可接受的载体或辅料过筛尺寸为50-150目。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310306191.3A CN116268390A (zh) | 2023-03-27 | 2023-03-27 | 一种提高记忆力、学习力和认知力的组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310306191.3A CN116268390A (zh) | 2023-03-27 | 2023-03-27 | 一种提高记忆力、学习力和认知力的组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116268390A true CN116268390A (zh) | 2023-06-23 |
Family
ID=86788468
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310306191.3A Pending CN116268390A (zh) | 2023-03-27 | 2023-03-27 | 一种提高记忆力、学习力和认知力的组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116268390A (zh) |
-
2023
- 2023-03-27 CN CN202310306191.3A patent/CN116268390A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hayashi et al. | Effect of astaxanthin-rich extract derived from Paracoccus carotinifaciens on cognitive function in middle-aged and older individuals | |
EP2440206B1 (en) | Trigonellin as a muscle stimulant | |
US8124139B2 (en) | Compound preparation for quickly reducing oxidative stress and preparation of the same | |
AU2008319747B2 (en) | Anti-fatigue agent comprising amino acid composition | |
JP2004537577A (ja) | 温血動物のストレス状態の予防用及び治療用の(リゾ)ホスファチジルセリン含有製剤 | |
WO2011051742A1 (en) | Preparation comprising amino acids and plants and its activity in the alcohol detoxification | |
CN110037268A (zh) | 一种改善睡眠的美容养颜果冻及其制作方法 | |
CN102160664A (zh) | 儿童营养饮料 | |
US20210128664A1 (en) | Agent for Activating Astrocyte Glucose Metabolism | |
CN112315995A (zh) | 一种含有元宝枫籽油的组合物及其制备方法 | |
CN103190483A (zh) | 儿童成长奶茶 | |
US20080085330A1 (en) | Compounds for stimulating stem cell proliferation including spirulina | |
EP2859896A1 (en) | Pharmaceutical compositions for the treatment of muscular disorders | |
AT513274B1 (de) | Nahrungsergänzungsmittel | |
US20170035721A1 (en) | Composition for preventing or improving peripheral neuropathy | |
CN111053798B (zh) | 一种富含愉悦激素前体的葵花籽组合物及抗抑郁应用 | |
CN107028169A (zh) | 一种改善记忆力的组合物及其制备方法 | |
CN111493315A (zh) | 一种改善记忆抗氧化组合物及其应用 | |
CN116268390A (zh) | 一种提高记忆力、学习力和认知力的组合物及其制备方法 | |
CN109673802A (zh) | 一种磷脂酰丝氨酸益智仁压片糖果及制备方法和应用 | |
CN108175808A (zh) | 一种药物组合物及其应用 | |
US20090017136A1 (en) | Formulation to prevent and treat fibromyalgia, depression and other muscle and nervous system disorders | |
US20080089905A1 (en) | COMPOUNDS FOR STIMULATING STEM CELL PROLIFERATION INCLUDING AFA-OMEGA (EtOH) | |
RU2436415C2 (ru) | Композиция биологически активных веществ на основе бетулина с регулируемой скоростью высвобождения компонентов для снижения степени алкогольного опьянения, предупреждения и снятия алкогольной интоксикации и похмельного синдрома | |
KR101929353B1 (ko) | 항우울 또는 항불안 활성을 갖는 쥐오줌풀 어린잎 추출물을 함유하는 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |